The hypothalamus is a region of the brain about the size of an almond. Despite its small size, it functions as the body's master regulator of hunger, fullness, and energy expenditure. When the hypothalamus is damaged — most commonly by surgical removal of a brain tumor, but also by traumatic brain injury, stroke, or severe inflammation — the signaling pathway that tells the body when it has eaten enough is broken. Patients experience constant hunger, a slowed metabolism, and rapid weight gain that standard weight-loss approaches cannot reverse.
This condition, known as acquired hypothalamic obesity (AHO), has never had an approved treatment. That changed in July 2026, when the FDA approved setmelanotide (brand name Imcivree) for patients aged four years and older with AHO. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist — a molecule that mimics the natural signal that the damaged hypothalamus can no longer produce. By binding to MC4R receptors in the brain, the drug restores the broken "I'm full" signal, suppressing appetite and increasing energy expenditure.
The approval was based on the phase 3 TRANSCEND clinical trial, published in the New England Journal of Medicine. In the largest and longest study ever conducted for AHO, 120 participants aged 4 to 66 years were randomized to receive either setmelanotide or a placebo for 52 weeks. The results were striking: patients treated with setmelanotide experienced an average 16.5 percent reduction in body mass index (BMI), while the placebo group saw an average 3.3 percent increase. Eight out of every 10 treated patients reduced their BMI by at least 5 percent. Participants also reported meaningful improvements in hunger, a symptom that makes the condition especially difficult to manage. The medication was generally well tolerated, with no new safety concerns identified during the study.
The broader significance of this approval extends beyond the relatively small population of AHO patients. It demonstrates that obesity can be treated by targeting its biological root causes rather than relying solely on behavioral interventions. The MC4R pathway is the same pathway involved in several genetic forms of obesity, and setmelanotide was originally approved in 2020 for certain rare genetic obesity syndromes. The TRANSCEND trial proves that the same pathway-based approach works even when the damage is acquired rather than inherited — a principle that could inform the development of next-generation obesity treatments for more common forms of the disease.
Knowledge takeaway: Setmelanotide is the first FDA-approved treatment for acquired hypothalamic obesity, a condition caused by brain damage that disrupts hunger signaling; the phase 3 TRANSCEND trial showed 16.5% average BMI reduction vs 3.3% increase in the placebo group; the drug replaces the missing MC4R signal in the hypothalamus, effectively restoring the brain's ability to regulate appetite and energy expenditure.